发明授权
US08628775B2 Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds
有权
用多聚体P-选择蛋白和/或E-选择素化合物降低T细胞介导的免疫应答的方法
- 专利标题： Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds
- 专利标题（中）： 用多聚体P-选择蛋白和/或E-选择素化合物降低T细胞介导的免疫应答的方法
-
申请号： US12562515申请日： 2009-09-18
-
公开(公告)号： US08628775B2公开(公告)日： 2014-01-14
- 发明人: Rong-Hwa Lin , Chung Nan Chang
- 申请人： Rong-Hwa Lin , Chung Nan Chang
- 申请人地址： NL Cm Amsterdam Zuidoost
- 专利权人： AbGenomics Cooperatief U.A.
- 当前专利权人： AbGenomics Cooperatief U.A.
- 当前专利权人地址： NL Cm Amsterdam Zuidoost
- 代理机构： Wolf, Greenfield & Sacks, P.C.
- 主分类号： A61K38/17
- IPC分类号： A61K38/17 ; C07K14/435
摘要：
Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as inflammatory diseases, autoimmune diseases, transplant rejection, and allergic diseases.
公开/授权文献
- US20100080819A1 MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1 公开/授权日：2010-04-01
信息查询
IPC分类:
